You need JavaScript to view this

Phase II study of induction chemotherapy followed by radiotherapy combined with daily cisplatin in stage III inoperable non-small cell lung cancer (NSCLC)

Abstract

Purpose: Results of radical radiotherapy in the treatment of inoperable NSCLC can be improved by either concurrent daily low-dose Cisplatin as radiosensitizer (Shaake-Koning, N Engl J Med, 1992; 326: 524) or by using neoadiuvant chemotherapy (Dillman, N Engl J Med, 1990; 323: 940). The aim of present study was to evaluate the activity and feasibility of a new chemo-radiotherapy (CT-RT) regimen in which both strategies of RT improvement will be used. Methods: Thirty consecutive patients (pts) were treated with induction CT (Cisplatin 100 mg/m{sup 2} i.v. day 1,22 + Vinblastine 5 mg/m{sup 2} i.v. day 1,8,15,22,29) followed by RT (60 Gy/30 fractions in 6 wks) combined with Cisplatin 5 mg/m{sup 2} daily before RT. Patients' characteristics were: 29 pts were male and 1 female; median age 60.5 yrs (range 44-69); median PS 1 (range 0-1); 21 squamous cell carcinoma and 9 adenocarcinoma; stage III A in 9 pts and stage IIIB in 21 pts. Results: Twenty-three pts were evaluable for RT plus daily Cisplatin toxicity and 29 for CT toxicity (according to WHO). For RT plus daily cisplatin hematological toxicity consisted of grade III leukopenia in 22%, grade III anemia 9% and grade III thrombocytopenia in 9% of pts. Only  More>>
Publication Date:
Jul 01, 1997
Product Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 39; Journal Issue: 2,suppl.1; Other Information: PII: S0360301697809121; Copyright (c) 1997 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); PBD: 1997
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ANEMIAS; ANTIMITOTIC DRUGS; CARCINOMAS; CHEMOTHERAPY; COMBINED THERAPY; LEUKOPENIA; LUNGS; PATIENTS; RADIOSENSITIZERS; RADIOTHERAPY; SURVIVAL TIME; TOXICITY
OSTI ID:
20423384
Country of Origin:
United States
Language:
English
Other Identifying Numbers:
Journal ID: ISSN 0360-3016; IOBPD3; TRN: US03R3949007057
Submitting Site:
INIS
Size:
page(s) 313
Announcement Date:
Feb 17, 2004

Citation Formats

Scolaro, T, Ardizzoni, A, Giudici, S, Grossi, F, Cosso, M, Pennucci, M C, Bacigalupo, A, Rosso, R, and Vitale, V. Phase II study of induction chemotherapy followed by radiotherapy combined with daily cisplatin in stage III inoperable non-small cell lung cancer (NSCLC). United States: N. p., 1997. Web. doi:10.1016/S0360-3016(97)80912-1.
Scolaro, T, Ardizzoni, A, Giudici, S, Grossi, F, Cosso, M, Pennucci, M C, Bacigalupo, A, Rosso, R, & Vitale, V. Phase II study of induction chemotherapy followed by radiotherapy combined with daily cisplatin in stage III inoperable non-small cell lung cancer (NSCLC). United States. doi:10.1016/S0360-3016(97)80912-1.
Scolaro, T, Ardizzoni, A, Giudici, S, Grossi, F, Cosso, M, Pennucci, M C, Bacigalupo, A, Rosso, R, and Vitale, V. 1997. "Phase II study of induction chemotherapy followed by radiotherapy combined with daily cisplatin in stage III inoperable non-small cell lung cancer (NSCLC)." United States. doi:10.1016/S0360-3016(97)80912-1. https://www.osti.gov/servlets/purl/10.1016/S0360-3016(97)80912-1.
@misc{etde_20423384,
title = {Phase II study of induction chemotherapy followed by radiotherapy combined with daily cisplatin in stage III inoperable non-small cell lung cancer (NSCLC)}
author = {Scolaro, T, Ardizzoni, A, Giudici, S, Grossi, F, Cosso, M, Pennucci, M C, Bacigalupo, A, Rosso, R, and Vitale, V}
abstractNote = {Purpose: Results of radical radiotherapy in the treatment of inoperable NSCLC can be improved by either concurrent daily low-dose Cisplatin as radiosensitizer (Shaake-Koning, N Engl J Med, 1992; 326: 524) or by using neoadiuvant chemotherapy (Dillman, N Engl J Med, 1990; 323: 940). The aim of present study was to evaluate the activity and feasibility of a new chemo-radiotherapy (CT-RT) regimen in which both strategies of RT improvement will be used. Methods: Thirty consecutive patients (pts) were treated with induction CT (Cisplatin 100 mg/m{sup 2} i.v. day 1,22 + Vinblastine 5 mg/m{sup 2} i.v. day 1,8,15,22,29) followed by RT (60 Gy/30 fractions in 6 wks) combined with Cisplatin 5 mg/m{sup 2} daily before RT. Patients' characteristics were: 29 pts were male and 1 female; median age 60.5 yrs (range 44-69); median PS 1 (range 0-1); 21 squamous cell carcinoma and 9 adenocarcinoma; stage III A in 9 pts and stage IIIB in 21 pts. Results: Twenty-three pts were evaluable for RT plus daily Cisplatin toxicity and 29 for CT toxicity (according to WHO). For RT plus daily cisplatin hematological toxicity consisted of grade III leukopenia in 22%, grade III anemia 9% and grade III thrombocytopenia in 9% of pts. Only 2 patients developed severe esophagitis. Only one case of radiation pneumonitis was reported. For induction CT hematological toxicity consisted of grade III-IV leukopenia in 31%, grade II anemia 10% and grade IV thrombocitopenia in 14% of cases. Non-hematological toxicity consisted mainly of grade I peripheral neuropaty and occured in 17% of pts. One case of minor hearing loss and 4 cases of tinnitus were observed at the end of treatment. Twenty-seven pts were evaluable for response. Response rate was 59% with 7 CRs (26%) and 9 PRs (33%); 1 patient had SD (4%), 5 pts PD (20%) and 5 pts (19%) died early (3 for early progression, 1 for toxicity and 1 for cardiac failure). All pts with CR are still alive with a median event-free survival of 23.9 months (range 12.3-41.9). Actuarial overall 1, 2 and 3 year survival were 52%, 34% and 34% respectively. Conclusions: Our preliminary results suggest that this CT-RT regimen is feasible and active in the treatment of inoperable NSCLC.}
doi = {10.1016/S0360-3016(97)80912-1}
journal = {International Journal of Radiation Oncology, Biology and Physics}
issue = {2,suppl.1}
volume = {39}
journal type = {AC}
place = {United States}
year = {1997}
month = {Jul}
}